Last reviewed 2026-04-22 · How we verify

Third generation fluoroquinolone

Third-generation fluoroquinolones inhibit bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms.

Third-generation fluoroquinolones inhibit bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms. Used for Community-acquired pneumonia, Acute bacterial sinusitis, Acute exacerbation of chronic bronchitis.

At a glance

Mechanism of action

These agents are broad-spectrum fluoroquinolone antibiotics with enhanced activity against gram-positive bacteria and atypical pathogens compared to earlier generations. They work by binding to and inhibiting bacterial topoisomerases, enzymes essential for DNA unwinding and replication, leading to bacterial cell death. Third-generation fluoroquinolones (such as levofloxacin and moxifloxacin) have improved pharmacokinetics and tissue penetration compared to first and second-generation agents.

Approved indications

• Community-acquired pneumonia
• Acute bacterial sinusitis
• Acute exacerbation of chronic bronchitis
• Complicated urinary tract infections
• Uncomplicated urinary tract infections

Common side effects

• Nausea
• Diarrhea
• Headache
• Tendinopathy
• QT prolongation
• Photosensitivity

Key clinical trials

• Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT) (PHASE3)
• Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli (PHASE2)
• Treatment of Chronic Bacterial Prostatitis (PHASE4)
• Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.